InMed Pharmaceuticals Files 8-K
Ticker: INM · Form: 8-K · Filed: Feb 3, 2025 · CIK: 1728328
Sentiment: neutral
Topics: sec-filing, 8-k, regulation-fd
TL;DR
InMed Pharma filed a standard 8-K, no major news.
AI Summary
InMed Pharmaceuticals Inc. filed an 8-K on February 3, 2025, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain specific financial figures or material events beyond the standard reporting requirements.
Why It Matters
This 8-K filing indicates routine corporate reporting by InMed Pharmaceuticals Inc. to the SEC, without disclosing specific new material events.
Risk Assessment
Risk Level: low — The filing is a routine 8-K with no disclosed material events or financial changes, indicating low immediate risk.
Key Players & Entities
- InMed Pharmaceuticals Inc. (company) — Filer of the 8-K report
- February 3, 2025 (date) — Date of the earliest event reported
- 001-39685 (other) — Commission File Number for InMed Pharmaceuticals Inc.
- 98-1428279 (other) — IRS Employer Identification No. for InMed Pharmaceuticals Inc.
FAQ
What is the primary purpose of this 8-K filing for InMed Pharmaceuticals Inc.?
The primary purpose is to report a Regulation FD Disclosure and Financial Statements and Exhibits as of February 3, 2025.
What is the exact date of the earliest event reported in this filing?
The date of the earliest event reported is February 3, 2025.
What is the Commission File Number for InMed Pharmaceuticals Inc.?
The Commission File Number for InMed Pharmaceuticals Inc. is 001-39685.
Where is InMed Pharmaceuticals Inc. headquartered?
InMed Pharmaceuticals Inc.'s principal executive offices are located at Suite 1445 - 885 W. Georgia Street, Vancouver, B.C. Canada V6C 3E8.
Does this filing disclose any specific new material events or financial results?
No, this filing primarily indicates routine reporting and does not disclose specific new material events or financial results beyond the standard categories.
Filing Stats: 549 words · 2 min read · ~2 pages · Grade level 10.8 · Accepted 2025-02-03 11:20:07
Filing Documents
- ea0229633-8k_inmed.htm (8-K) — 34KB
- ea022963301ex99-1_inmed.htm (EX-99.1) — 17KB
- ex99-1_001.jpg (GRAPHIC) — 5KB
- 0001213900-25-009213.txt ( ) — 234KB
- inm-20250203.xsd (EX-101.SCH) — 3KB
- inm-20250203_lab.xml (EX-101.LAB) — 33KB
- inm-20250203_pre.xml (EX-101.PRE) — 22KB
- ea0229633-8k_inmed_htm.xml (XML) — 4KB
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits: The following exhibits shall be deemed to be furnished, and not filed: Exhibit No. Description 99.1 News release, dated February 3, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document and included as Exhibit 101) 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. INMED PHARMACEUTICALS INC. Date: February 3, 2025 By: /s/ Eric A Adams Eric A Adams President & CEO 2